Herniación uncal secundaria a plasmocitoma intracraneal

González, Ulises García; Vargas, Samuel Romero; Rivera, Bernarda Jara; Vega, Rosalba; González, Ernesto Ledesma; García, Rafael Ruvalcaba; Amador, Juan Luis Gómez; Gómez-Llata, Sergio
January 2007
Archivos de Neurociencias;ene-mar2007, Vol. 12 Issue 1, p55
Academic Journal
Describe a case of a 51 year old female with medical background of multiple myeloma that complained of right hemiparesis and neurological examination revealed signs of intracranial hypertension and uncal herniation. Computed tomography showed an osteolitic epidural high-density mass with marked homogeneous enhancement. At surgery a soft yellowish tumor was totally resected. The pathological analysis revealed a plasmacytoma. After radiation, the postoperative course over the following ten months was uneventful. However, since clinicopatholgic studies have identified extramedullary plasmacytomas with skull bone location, the epidural mass effect is an infrequent clinical presentation. Clinical, neuroradiological features and surgical treatment of this unusual lesion are discussed.


Related Articles

  • Extramedullary Plasmacytoma of the Parotid Gland Masquerading as Poorly Differentiated Carcinoma: Pitfalls in Initial Diagnosis and Subsequent Management. Teng Lye Khoo; Ewe Seng Ch'ng; Basiron, Normala; Yusoff, Suryati Mohd // International Medical Journal;Oct2013, Vol. 20 Issue 5, p564 

    Introduction: Extramedullary plasmacytoma is a localized clonal proliferation of plasma cells arising in regions other than bone marrow and without evidence of multiple myeloma. Its occurrence in parotid gland is extremely rare with limited published cases. Clinical summary: We report such a...

  • CITATIONS AND CLINICIANS' NOTES: MYELOMA.  // Current Medical Literature: Leukemia & Lymphoma;2004, Vol. 12 Issue 4, p90 

    Presents citations and clinicians' notes on myeloma. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization; Efficacy and safety of imatinib in adult patients with c-kit positive acute myeloid leukemia; Relation between CXC chemokine receptor 4 expression, Flt3...

  • Continuous therapy with lenalidomide in multiple myeloma.  // British Journal of Hospital Medicine (17508460);Jan2010, Vol. 71 Issue 1, p10 

    The article offers information on the data that evaluates the continuous therapy with Revlimid across all stage of multiple myeloma in the U.S. The data presented during the American Society of Hematology congress demonstrated that lenalidomide has a significant clinical potential in active...

  • Plasma Cell Myeloma and Related Neoplasms. Lorsbach, Robert B.; Hsi, Eric D.; Dogan, Ahmet; Fend, Falko // American Journal of Clinical Pathology;Aug2011, Vol. 136 Issue 2, p168 

    Session 1 of the 2009 Workshop of the Society for Hematopathology/European Association of Haematopathology, Cleveland, OH, focused on plasma cell neoplasms. This report summarizes the salient diagnostic, clinical, and genetic features of plasma cell myeloma (PCM) and related neoplasms. Based on...

  • Multiple Myeloma in a Patient with Castleman's Disease. Sumrall, Ashley; Shumaker, Grace; Elkins, Stephanie // Internet Journal of Hematology;2008, Vol. 4 Issue 2, p7 

    Multiple myeloma is characterized by malignant plasma cells in the bone marrow, overproduction of a monoclonal protein, and lytic bony destruction. It is an incurable disease accounting for approximately 20 percent of deaths from hematologic malignancy and 2 percent of deaths from all cancers....

  • Multiple Osteolytic Lesions. Vinayachandran, Divya; Sankarapandian, Sathasivasubramanian // Journal of Clinical Imaging Science;Jan-Mar2013 Supplement, Vol. 3, p1 

    Several systemic diseases initially present with various oral manifestations. Investigation of these oral symptoms may at times lead to the diagnosis of grave underlying life-threatening conditions. We present one such case, where the patient manifested with gross enlargement of the mandible,...

  • Extramedullary progression of multiple myeloma despite a good response in the bone marrow in a patient following autologous stem cell transplantation. Kose, Mustafa; Sonnez, Mehmet; Cobanoglu, Umit; Yilmaz, Mustafa; Karti, S. Sami; Ovali, Ercument; Ozoran, Yavuz // Turkish Journal of Cancer;Apr2003, Vol. 33 Issue 2, p102 

    Extramedullary plasmacytomas may be seen in the course of multiple myeloma. However, extramedullary progression despite good response in the bone marrow to therapy is extremely rare. Recently, two cases of multiple with extramedullary progression despite continued response to thalidomide in the...

  • Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. Terpos, Evangelos; Politou, Marianna; Rahemtulla, Amin // Journal of Cancer Research & Clinical Oncology;Oct2004, Vol. 130 Issue 10, p623 

    Bortezomib (VELCADE) is a proteasome inhibitor, which has been recently used for the treatment of relapsed/refractory multiple myeloma (MM) with encouraging results. Tumour lysis syndrome (TLS) has been described during chemotherapy for many haematological malignancies, such as acute...

  • Cure of multiple myeloma – more hype, less reality. Hari, P.; Pasquini, M. C.; Vesole, D. H. // Bone Marrow Transplantation;Jan2006, Vol. 37 Issue 1, p1 

    Randomized studies have firmly established the role of autologous transplant as initial therapy in multiple myeloma (MM). Indeed, MM has emerged as the commonest indication for autologous SCT in North America. The conceptual basis for high-dose therapy is the goal of complete remission (CR)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics